Intravitreal Anti-VEGF Therapy for Retinal Vein Occlusion
Primary Indication: Macular Edema with Vision Loss
- The American Academy of Ophthalmology recommends anti-VEGF agents as the preferred first-line therapy for macular edema causing vision loss in both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), with FDA-approved agents including ranibizumab and aflibercept 1, 2
- The core indication for anti-VEGF therapy in RVO is macular edema documented on OCT that causes visual acuity impairment, representing a strong recommendation based on multiple randomized controlled trials demonstrating superior visual outcomes compared to observation or laser therapy alone 1, 2, 3
Evidence Supporting First-Line Use
- For BRVO, anti-VEGF agents demonstrate superior efficacy over grid laser photocoagulation, with the VIBRANT trial showing significant visual gains with aflibercept compared to laser treatment 3
- For CRVO, multiple landmark trials (CRUISE with ranibizumab, COPERNICUS and GALILEO with aflibercept) demonstrated 15-letter gains in 56-60% of treated eyes versus 12-20% with sham injections 1, 2, 3
- Bevacizumab (off-label) showed comparable efficacy with 15-letter gain in 60% of treated eyes in randomized trials, and SCORE2 demonstrated similar visual outcomes between aflibercept and bevacizumab at 6 months 1, 2
Treatment Algorithm Based on RVO Type
- For BRVO with macular edema, initiate anti-VEGF therapy (ranibizumab 0.5 mg or aflibercept 2 mg monthly initially) for visual acuity ≤20/40 with macular edema 1, 2, 6
- For CRVO with macular edema, begin anti-VEGF therapy immediately (same dosing as BRVO) for any vision-threatening macular edema 1, 2, 3
Safety Profile and Risk-Benefit Analysis
- Anti-VEGF agents have a favorable risk-to-benefit profile compared to corticosteroids, with severe adverse events being uncommon, such as endophthalmitis (0.0-0.9%), retinal detachment, and elevated IOP 1, 2, 3
- No increased arterial thromboembolic events demonstrated in meta-analyses 1, 2